Morphic Holding, Inc. (MORF)
Upgrades & Downgrades
Latest MORF news
Strength Seen in Morphic Holding, Inc. (MORF): Can Its 7% Jump Turn into More Strength?
27 April 2022
Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric...
Morphic Holding, Inc. (MORF) Upgraded to Buy: What Does It Mean for the Stock?
5 January 2022
Morphic Holding, Inc. (MORF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Morphic: Pioneering Integrin Medicines
13 October 2021
Morphic is pursuing a multi-billion opportunity of replacing biologics modulating integrins with small molecules. The company is founded by the individual who discovered integrins and has built a uniq...
New Strong Sell Stocks for September 16th
16 September 2021
CLMT, FANH, and MORF have been added to the Zacks Rank #5 (Strong Sell) List on September 16, 2021.
Morphic Therapeutic Announces Appointment of Nisha Nanda, Ph.D., to Board of Directors
23 August 2021
WALTHAM, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ch...
Morphic Holding, Inc. (MORF) Reports Q2 Loss, Misses Revenue Estimates
4 August 2021
Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -40.00% and -35.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Morphic Therapeutic Shares New Positive MORF-057 Data From IBD Study
9 July 2021
Morphic Therapeutic (NASDAQ: MORF) has announced additional data from its Phase 1 trial evaluating MORF-057 for inflammatory bowel disease (IBD). The data were shared at the Congress of European Croh...
Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate ...
9 July 2021
MORF-057 well tolerated across all phase 1 cohorts
Strength Seen in Morphic Holding, Inc. (MORF): Can Its 6% Jump Turn into More Strength?
3 June 2021
Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near...